A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
Clinical trial NCT01250119 · COMPLETED
Trial details
- NCT number
- NCT01250119
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-01
- Primary completion
- 2014-05-01
- Enrollment
- 688
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.